Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3009385 · 1 trial · 1 indication
The number of participants with 1 or more AEs assessed as related to the study drug and is summarized cumulatively. In addition, the number of participants with 1 or more serious AEs is summarized cumulatively. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| 0.3 mg LY3009385 | EXPERIMENTAL | LY3009385: 0.3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1 |
| 1 mg LY3009385 | EXPERIMENTAL | LY3009385: 1 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1 |
| 3 mg LY3009385 | EXPERIMENTAL | LY3009385: 3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1 |
| 9 mg LY3009385 | EXPERIMENTAL | LY3009385: 9 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1 |
| 22 mg LY3009385 | EXPERIMENTAL | LY3009385: 22 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1 |
| 54 mg LY3009385 | EXPERIMENTAL | LY3009385: 54 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1 |
| Placebo | PLACEBO_COMPARATOR | Placebo: saline, subcutaneous (SC) injection, single dose on Day 1 |
| Name | Type | Description |
|---|---|---|
| LY3009385 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Are a healthy male or a female who cannot become pregnant * Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m\^2) at screening * Have blood pressure, pulse rate, as well as blood and urine laboratory test results acceptable for the study * Have vei...
LY3009385 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is being developed by Eli Lilly and Company and is currently in Phase 1 clinical development.
The specific molecular target of LY3009385 has not been disclosed. It is a small molecule being investigated for its potential role in treating Type 2 Diabetes Mellitus, but its mechanism of action is not publicly available.
LY3009385 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is currently in Phase 1 clinical trials.
LY3009385 is in Phase 1 clinical development. It has completed one first-in-human study in healthy participants, and it remains an investigational drug that has not been approved by regulatory authorities.
LY3009385 has one completed Phase 1 trial, NCT01477567, titled 'A First-in-Human Study of LY3009385 in Healthy Participants.' This randomized, double-blind, placebo-controlled study enrolled 40 participants in Singapore and included healthy volunteers.
No alternative names for LY3009385 have been disclosed. It is identified solely by its development code LY3009385 and is not known to be marketed under any other name.